.png)
Atopic Dermatitis Study with Sequential's Cutting-Edge Microbiome Testing
Why Microbiome Testing for Atopic Dermatitis?
Atopic dermatitis (AD), a chronic inflammatory skin condition, affects around 31.6 million people in the U.S., with 15-20% of children globally and 7.3% of U.S. adults experiencing the condition (National Eczema Association). AD often results from a combination of genetic predisposition and environmental triggers, such as irritants in cosmetic products. Disruptions to the skin’s microbiome play a significant role in the disease's development and severity. Imbalances in beneficial and harmful microbes can exacerbate AD, highlighting the importance of targeted treatments.
In vivo testing for products aimed at managing AD is essential because it allows researchers to understand how formulations impact both the skin barrier and microbiome in real-world conditions. Properly tested products can help reduce irritation and avoid worsening symptoms, offering a science-backed approach to skincare for those with AD.
Sequential is leading the way in microbiome testing for the industry. With a specialized focus on skin conditions, we have developed an innovative solution tailored to help you understand the root causes of AD at the microbial level. Our proprietary sequencing panel is designed specifically to offer in-depth analysis of AD-associated microbiota, giving you the tools to transform skincare solutions.
Customized Analysis
Tailored insights specific to AD-prone skin, allowing your R&D team to develop more personalized and effective products.
Actionable Data
Leverage detailed reports to guide formulation decisions and validate product efficacy with precision.
Product Innovation
New AD treatments or enhancing existing lines, our data helps you create targeted solutions with proven results.
Precision Sequencing
Target specific microbial communities associated with AD development and severity.
Smart Probes™
Our dedicated team of scientists has developed a revolutionary method for evaluating microbes through our Smart Probes™. This proprietary panel includes 23 key microbes that we have specifically identified as having the most significant impact on skin health. To further understand the intricate relationship between atopic dermatitis (AD) and the skin microbiome, we use qPCR technology. This advanced technique allows us to precisely quantify microbial populations on the skin, providing deeper insights into how AD affects the microbiome.
By closely monitoring how products interact with both beneficial and harmful microbes, companies can create solutions for AD but also restore a healthy balance to the skin’s ecosystem.
Atopic Dermatitis Panel Targets
Staphylococcus aureus
This bacterium is frequently found in higher numbers on the skin of individuals with atopic dermatitis. It can exacerbate inflammation and contribute to skin barrier disruption.
Malassezia spp
This genus of yeast, which is part of the normal skin flora, can become overgrown in individuals with atopic dermatitis, potentially aggravating symptoms.
Staphylococcus epidermidis
While generally considered a commensal organism, imbalances in its population, along with other microbes, can influence the skin's health and contribute to atopic dermatitis symptoms.
Industry Leader in Absolute Quantification
Sequential’s Smart Probe™ qPCR approach to microbiome analysis can resolve species and subspecies, giving statistically significant findings between skin conditions on in vivo human samples, compared to conventional sequencing approaches.
